Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies (Q91016110)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

title

Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

author name string

Jennifer G Robinson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

Frederick J Raal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

Robert Dufour

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

David Sullivan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

Helina Kassahun

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

Yuhui Ma

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

Scott M Wasserman

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

Michael J Koren

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

publication date

21 October 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

page(s)

1328-1335

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

18 April 2020

cites work

1 reference

7 January 2021

An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia

1 reference

7 January 2021

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

1 reference

7 January 2021

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

7 January 2021

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

7 January 2021

Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials

1 reference

7 January 2021

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

1 reference

7 January 2021

Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.

1 reference

7 January 2021

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology T

1 reference

7 January 2021

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

7 January 2021

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

1 reference

7 January 2021

Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study

1 reference

7 January 2021

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

1 reference

7 January 2021

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

1 reference

7 January 2021

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

1 reference

7 January 2021

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

1 reference

7 January 2021

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

1 reference

7 January 2021

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

1 reference

7 January 2021

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

1 reference

7 January 2021

Testing for qualitative interactions between treatment effects and patient subsets

1 reference

7 January 2021

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

1 reference

7 January 2021

Plasma PCSK9 levels correlate with cholesterol in men but not in women

1 reference

7 January 2021

The low-density lipoprotein receptor is regulated by estrogen and forms a functional complex with the estrogen-regulated protein ezrin in pituitary GH3 somatolactotropes

1 reference

7 January 2021

Androgen Receptor-Mediated Antagonism of Estrogen-Dependent Low Density Lipoprotein Receptor Transcription in Cultured Hepatocytes

1 reference

7 January 2021

Hormone replacement therapy, hormone levels, and lipoprotein cholesterol concentrations in elderly women

1 reference

7 January 2021

Genetic and metabolic determinants of plasma PCSK9 levels

1 reference

7 January 2021

Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events

1 reference

7 January 2021

Independent Link Between Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and FABP4 in a General Population Without Medication

1 reference

7 January 2021

Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition?

1 reference

7 January 2021

Identifiers

DOI

10.1002/CLC.23049

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30120772 AND SRC:MED&resulttype=core&format=json

18 April 2020

PubMed publication ID

30120772

1 reference